An interventional study of Intraumbilical oxytocin and Intravenous oxytocin in Labor, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
There is always a debate for choosing the best method for management of the third stage of labour (TSL) in the general practice for reducing the duration of TSL. Although intravenous oxytocin is more extensively used in general practice for managing TSL than intraumbilical, it still needs to be properly investigated among local populations and in local settings.
The findings of this study could identify the better route of oxytocin injection that could guide clinicians and health providers to opt for the better route in their routine practice for the management of TSL in order to reduce the morbidity and mortality of the patients, especially for developing countries like Pakistan, where most of the deliveries are conducted at peripheral or rural centers by a nurse, midwife, or a trained dai.
RESnTEC, Institute of Research is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.
Drug: Intraumbilical oxytocin
Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.
Drug: Intravenous oxytocin
Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.
Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.
Duration of the third stage labour
The duration of the third stage labour was measured from the completed delivery of the newborn until the completed delivery of the placenta.
Time frame: 30 minutes
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Mar 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxytocin
RESnTEC, Institute of Research